Next‑generation sequencing failure rates in rare tumors: A real‑world single‑institution analysis.

ABSTRACT: Reported next-generation sequencing (NGS) failure rates vary widely and are primarily based on studies of common tumor types. The present study aimed to estimate NGS failure rates in rare tumors and their association with preanalytical variables and sequencing methods in a single institution. Patients with sarcomas, rare carcinomas, and rare melanomas who underwent NGS between January 2022 and October 2023 were eligible for participation in the present study. NGS was performed as whole exome/transcriptome sequencing (WETS) based on hybrid capture or multigene commercial targeted panel. Clinicopathological and NGS-related data were extracted from clinical charts. Univariable logistic regression models were constructed with the outcome variable NGS failure and the following explanatory varia

SUBMITTER: Itkin B 

PROVIDER: S-EPMC11956127 | biostudies-literature | 2025 May-Jun

REPOSITORIES: biostudies-literature